Literature DB >> 11493441

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

J W van Esser1, B van der Holt, E Meijer, H G Niesters, R Trenschel, S F Thijsen, A M van Loon, F Frassoni, A Bacigalupo, U W Schaefer, A D Osterhaus, J W Gratama, B Löwenberg, L F Verdonck, J J Cornelissen.   

Abstract

Reactivation of the Epstein-Barr virus (EBV) after allogeneic stem cell transplantation (allo-SCT) may evoke a protective cellular immune response or may be complicated by the development of EBV-lymphoproliferative disease (EBV-LPD). So far, very little is known about the incidence, recurrence, and sequelae of EBV reactivation following allo-SCT. EBV reactivation was retrospectively monitored in 85 EBV-seropositive recipients of a T-cell--depleted (TCD) allo-SCT and 65 EBV-seropositive recipients of an unmanipulated allo-SCT. Viral reactivation (more than 50 EBV genome equivalents [gEq]/mL) was monitored frequently by quantitative real-time plasma polymerase chain reaction until day 180 after SCT. Probabilities of developing viral reactivation were high after both unmanipulated and TCD-allogeneic SCT (31% +/- 6% versus 65% +/- 7%, respectively). A high CD34(+) cell number of the graft appeared as a novel significant predictor (P =.001) for EBV reactivation. Recurrent reactivation was observed more frequently in recipients of a TCD graft, and EBV-LPD occurred only after TCD-SCT. High-risk status, TCD, and use of antithymocyte globulin were predictive for developing EBV-LPD. Plasma EBV DNA quantitatively predicted EBV-LPD. The positive and negative predictive values of a viral load of 1000 gEq/mL were, respectively, 39% and 100% after TCD. Treatment-related mortality did not differ significantly between TCD and non-TCD transplants, but the incidence of chronic graft-versus-host disease was significantly less in TCD patients. It is concluded that EBV reactivation occurs frequently after TCD and unmanipulated allo-SCT, especially in recipients of grafts with high CD34(+) cell counts. EBV-LPD, however, occurred only after TCD, and EBV load quantitatively predicted EBV-LPD in recipients of a TCD graft. (Blood. 2001;98:972-978)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493441     DOI: 10.1182/blood.v98.4.972

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

Review 1.  Alternative donor transplants for severe aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation.

Authors:  Rianne Luderer; Marieke Kok; Hubert G M Niesters; Rob Schuurman; Okke de Weerdt; Steven F T Thijsen
Journal:  Mol Diagn       Date:  2005

Review 3.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 4.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 5.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

6.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

7.  Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.

Authors:  Junko Yamaguchi; Takahiro Fujino; Reiko Isa; Daichi Nishiyama; Saeko Kuwahara-Ota; Yuka Kawaji; Taku Tsukamoto; Yoshiaki Chinen; Yuji Shimura; Tsutomu Kobayashi; Shigeo Horiike; Kei Kohno; Shigeo Nakamura; Junya Kuroda
Journal:  Haematologica       Date:  2019-04-11       Impact factor: 9.941

8.  Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.

Authors:  Hongchen Liu; Xiaoli Zheng; Chengtao Zhang; Jiajun Xie; Beibei Gao; Jing Shao; Yan Yang; Hengxiang Wang; Jinsong Yan
Journal:  Front Med       Date:  2021-06-25       Impact factor: 4.592

9.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

10.  Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.

Authors:  Angela Mensen; Il-Kang Na; Ralf Häfer; Astrid Meerbach; Maria Schlecht; Marie-Luise Pietschmann; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-25       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.